Stemcells Inc (STEM) 1.09 $STEM
German Researchers Verify Positive, System-Wide Effect Of Pluristem's PLX Cell Therapy
Sharon di Stefano - Seeking Alpha - Wed Feb 11, 3:31PM CST
Pluristem Therapeutics Inc. (NASDAQ: PSTI ), maker of cell therapy for a wide variety of diseases, recently announced 12-month results from Phase I/II studies with its PLX-PAD off-the-shelf treatment for people who had undergone total hip...
PSTI: 2.91 (+0.01), CYTX: 0.47 (unch), STEM: 1.09 (-0.01), ATHX: 2.12 (unch), CUR: 3.41 (+0.13), CELG: 115.88 (+0.16)
Safety and Preliminary Efficacy of Human Neural Stem Cells in StemCells, Inc.'s Dry AMD Study to be Presented at Ophthalmology Conference
GlobeNewswire - Thu Feb 05, 7:07AM CST
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that Theodore Leng, MD, MS, Clinical Assistant Professor of Ophthalmology at the Byers Eye Institute at Stanford, Stanford University School of Medicine and a principal investigator on StemCells, Inc.'s Phase I/II study in dry age related macular degeneration will be presenting findings on the safety and preliminary efficacy of HuCNS-SC, human neural stem cells, for dry age related macular degeneration (AMD) at the Angiogenesis, Exudation and Degeneration 2015 symposium. Dr. Leng will present at 12:40 p.m. EST. AMD is the leading cause of blindness in people over the age of 50 and today there are no approved therapies to treat dry AMD. This symposium is hosted by the Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. The symposium will be held February 7, 2015 at the Mandarin Oriental Hotel in Miami, Florida.
STEM: 1.09 (-0.01)
StemCells, Inc. to Participate at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that Management will make a presentation on the Company's programs and operations at the 17 Annual BIO CEO & Investor Conference. Management is scheduled to speak at 8:30 a.m. EST on Monday, February 9, at the Waldorf Astoria in New York City.
STEM: 1.09 (-0.01)
Stem Cells Inc. Posts Letter to Shareholders
GlobeNewswire - Mon Jan 26, 7:10AM CST
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn.
STEM: 1.09 (-0.01)
StemCells Up 7.8%, Shares Break Through Resistance (STEM)
Comtex SmarTrend(R) - Tue Jan 06, 10:35AM CST
StemCells (NASDAQ:STEM) is one of today's best performing low-priced stocks, up 7.8% to $1.10 on 1.1x average daily volume. Thus far today, StemCells has traded 723,000 shares, vs. average volume of 647,000 shares per day. The stock has outperformed the Dow (7.8% to the Dow's -0.6%) and outperformed the S&P 500 (7.8% to the S&P's -0.6%) during today's trading.
STEM: 1.09 (-0.01)
Brainstorm Cell up on clinical trial results
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:25AM CST
FCSC: 4.75 (+0.50), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), STEM: 1.09 (-0.01), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Stock to Watch: StemCells Up 6.4% (STEM)
Comtex SmarTrend(R) - Thu Dec 18, 12:42PM CST
StemCells (NASDAQ:STEM) is one of today's best performing penny stocks, up 6.4% to $0.94 on 1.2x average daily volume. StemCells has traded 831,000 shares thus far today, vs. average volume of 715,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's 1.7%) and outperformed the S&P 500 (6.9% to the S&P's 1.8%) during today's trading.
STEM: 1.09 (-0.01)
First SCI patient transplanted with StemCells' HuCNS-SC
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 10:31AM CST
STEM: 1.09 (-0.01)
StemCells, Inc. Transplants First Participant in Phase II Clinical Trial in Cervical Spinal Cord Injury
GlobeNewswire - Thu Dec 18, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, announced today that it has transplanted the first subject in its Phase II Pathway Study assessing the efficacy of its proprietary HuCNS-SC (purified human neural stem cells) platform technology for the treatment of cervical spinal cord injury (SCI). The transplant was performed at the University of Miami Hospital within the Miller School of Medicine, home to The Miami Project to Cure Paralysis, one of the world's most comprehensive spinal cord injury research centers dedicated to finding effective treatments for paralysis.
STEM: 1.09 (-0.01)
Investors look to Lighten Up on Shares of StemCells, Shares Down 5.4% (STEM)
Comtex SmarTrend(R) - Mon Dec 15, 10:07AM CST
StemCells (NASDAQ:STEM) is one of today's worst performing penny stocks, down 5.4% to $0.97 on 1.3x average daily volume. StemCells has traded 830,000 shares thus far today, vs. average volume of 617,000 shares per day. The stock has underperformed the Dow (-5.4% to the Dow's -0.0%) and underperformed the S&P 500 (-5.4% to the S&P's 0.1%) during today's trading.
STEM: 1.09 (-0.01)
Brinson Patrick's Christopher S. James: All Catalysts Are Not Created Equal
Life Sciences Report - Seeking Alpha - Fri Dec 05, 7:55AM CST
Why do some good-news milestones cause stocks to languish, or even fall? Neurosurgeon Christopher James, managing director and senior biotechnology analyst at Brinson Patrick Securities, performs due diligence on stocks, in part, by connecting his...
BCRX: 10.06 (-0.09), STEM: 1.09 (-0.01), RTRX: 13.92 (+0.44), RGLS: 16.85 (-0.13), SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
StemCells, Inc. Hosts Leading Biotech Investors and Analysts at Inaugural Event
GlobeNewswire - Tue Dec 02, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM), a leader in the development of cell-based therapies for disorders of the central nervous system (CNS), hosted its first investor and analyst event in New York, on November 20, 2014.
STEM: 1.09 (-0.01)
StemCells, Inc. to Host Inaugural Investor and Analyst Event in New York
GlobeNewswire - Thu Nov 20, 9:11AM CST
StemCells, Inc. (Nasdaq:STEM), who pioneered the discovery and development of HuCNS-SC cells, a proprietary population of highly purified, expandable human neural stem cells and is leading the development of cell based therapies for the treatment of disorders of the central nervous system, will host its first investor and analyst event today, November 20, 2014, in New York.
STEM: 1.09 (-0.01)
A Timely Interview With BioTime's CEO And His Chief Commercial Officer
JMY Investments - at Seeking Alpha - Mon Nov 17, 10:39AM CST
BTX: 4.07 (+0.05), STEM: 1.09 (-0.01)
InVivo Therapeutics
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:56PM CST
STEM: 1.09 (-0.01), AST: 3.85 (+0.13), CUR: 3.41 (+0.13)
StemCells Inc. Faces Tough Times Ahead
Tom Franey - Seeking Alpha - Mon Nov 10, 9:36AM CST
StemCells Inc. (NASDAQ: STEM ) is a small cap biotech company primarily involved in stem cell research. Its stock is currently trading at $1.16, which is 50% of its recent highs. Disappointing Results In June of this year, STEM issued a press...
STEM: 1.09 (-0.01)
StemCells, Inc.: More Downside Risk Ahead
Biotech Research Group - Seeking Alpha - Fri Nov 07, 8:51AM CST
As an investor in the field of regenerative medicine and science, it is important to keep a focused eye on both the clinical accomplishments as well as the financial strength of the companies in which I invest. StemCells, Inc. (NASDAQ: STEM ) has...
STEM: 1.09 (-0.01)
StemCells beats by $0.12, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 7:24AM CST
STEM: 1.09 (-0.01)
StemCells, Inc. Reports Third Quarter 2014 Financial and Operating Results
GlobeNewswire - Wed Nov 05, 7:07AM CST
StemCells, Inc. (Nasdaq:STEM), which pioneered the discovery and development of HuCNS-SC cells, a proprietary population of highly purified, expandable human neural stem cells and is leading the development of cell based therapies for the treatment of disorders of the central nervous system, today reported financial results for the third quarter ended September 30, 2014.
STEM: 1.09 (-0.01)
German Researchers Verify Positive, System-Wide Effect Of Pluristem's PLX Cell Therapy
Sharon di Stefano - Seeking Alpha - Wed Feb 11, 3:31PM CST
Pluristem Therapeutics Inc. (NASDAQ: PSTI ), maker of cell therapy for a wide variety of diseases, recently announced 12-month results from Phase I/II studies with its PLX-PAD off-the-shelf treatment for people who had undergone total hip...
PSTI: 2.91 (+0.01), CYTX: 0.47 (unch), STEM: 1.09 (-0.01), ATHX: 2.12 (unch), CUR: 3.41 (+0.13), CELG: 115.88 (+0.16)
Safety and Preliminary Efficacy of Human Neural Stem Cells in StemCells, Inc.'s Dry AMD Study to be Presented at Ophthalmology Conference
GlobeNewswire - Thu Feb 05, 7:07AM CST
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, announced today that Theodore Leng, MD, MS, Clinical Assistant Professor of Ophthalmology at the Byers Eye Institute at Stanford, Stanford University School of Medicine and a principal investigator on StemCells, Inc.'s Phase I/II study in dry age related macular degeneration will be presenting findings on the safety and preliminary efficacy of HuCNS-SC, human neural stem cells, for dry age related macular degeneration (AMD) at the Angiogenesis, Exudation and Degeneration 2015 symposium. Dr. Leng will present at 12:40 p.m. EST. AMD is the leading cause of blindness in people over the age of 50 and today there are no approved therapies to treat dry AMD. This symposium is hosted by the Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. The symposium will be held February 7, 2015 at the Mandarin Oriental Hotel in Miami, Florida.
STEM: 1.09 (-0.01)
StemCells, Inc. to Participate at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM) announced today that Management will make a presentation on the Company's programs and operations at the 17 Annual BIO CEO & Investor Conference. Management is scheduled to speak at 8:30 a.m. EST on Monday, February 9, at the Waldorf Astoria in New York City.
STEM: 1.09 (-0.01)
Stem Cells Inc. Posts Letter to Shareholders
GlobeNewswire - Mon Jan 26, 7:10AM CST
StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, posted today the following Letter to Shareholders from its President and CEO, Martin McGlynn.
STEM: 1.09 (-0.01)
StemCells Up 7.8%, Shares Break Through Resistance (STEM)
Comtex SmarTrend(R) - Tue Jan 06, 10:35AM CST
StemCells (NASDAQ:STEM) is one of today's best performing low-priced stocks, up 7.8% to $1.10 on 1.1x average daily volume. Thus far today, StemCells has traded 723,000 shares, vs. average volume of 647,000 shares per day. The stock has outperformed the Dow (7.8% to the Dow's -0.6%) and outperformed the S&P 500 (7.8% to the S&P's -0.6%) during today's trading.
STEM: 1.09 (-0.01)
Brainstorm Cell up on clinical trial results
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 9:25AM CST
FCSC: 4.75 (+0.50), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), STEM: 1.09 (-0.01), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
Stock to Watch: StemCells Up 6.4% (STEM)
Comtex SmarTrend(R) - Thu Dec 18, 12:42PM CST
StemCells (NASDAQ:STEM) is one of today's best performing penny stocks, up 6.4% to $0.94 on 1.2x average daily volume. StemCells has traded 831,000 shares thus far today, vs. average volume of 715,000 shares per day. The stock has outperformed the Dow (6.9% to the Dow's 1.7%) and outperformed the S&P 500 (6.9% to the S&P's 1.8%) during today's trading.
STEM: 1.09 (-0.01)
First SCI patient transplanted with StemCells' HuCNS-SC
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 10:31AM CST
STEM: 1.09 (-0.01)
StemCells, Inc. Transplants First Participant in Phase II Clinical Trial in Cervical Spinal Cord Injury
GlobeNewswire - Thu Dec 18, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, announced today that it has transplanted the first subject in its Phase II Pathway Study assessing the efficacy of its proprietary HuCNS-SC (purified human neural stem cells) platform technology for the treatment of cervical spinal cord injury (SCI). The transplant was performed at the University of Miami Hospital within the Miller School of Medicine, home to The Miami Project to Cure Paralysis, one of the world's most comprehensive spinal cord injury research centers dedicated to finding effective treatments for paralysis.
STEM: 1.09 (-0.01)
Investors look to Lighten Up on Shares of StemCells, Shares Down 5.4% (STEM)
Comtex SmarTrend(R) - Mon Dec 15, 10:07AM CST
StemCells (NASDAQ:STEM) is one of today's worst performing penny stocks, down 5.4% to $0.97 on 1.3x average daily volume. StemCells has traded 830,000 shares thus far today, vs. average volume of 617,000 shares per day. The stock has underperformed the Dow (-5.4% to the Dow's -0.0%) and underperformed the S&P 500 (-5.4% to the S&P's 0.1%) during today's trading.
STEM: 1.09 (-0.01)
Brinson Patrick's Christopher S. James: All Catalysts Are Not Created Equal
Life Sciences Report - Seeking Alpha - Fri Dec 05, 7:55AM CST
Why do some good-news milestones cause stocks to languish, or even fall? Neurosurgeon Christopher James, managing director and senior biotechnology analyst at Brinson Patrick Securities, performs due diligence on stocks, in part, by connecting his...
BCRX: 10.06 (-0.09), STEM: 1.09 (-0.01), RTRX: 13.92 (+0.44), RGLS: 16.85 (-0.13), SNY: 49.42 (+0.82), MNKD: 7.00 (+0.02)
StemCells, Inc. Hosts Leading Biotech Investors and Analysts at Inaugural Event
GlobeNewswire - Tue Dec 02, 7:00AM CST
StemCells, Inc. (Nasdaq:STEM), a leader in the development of cell-based therapies for disorders of the central nervous system (CNS), hosted its first investor and analyst event in New York, on November 20, 2014.
STEM: 1.09 (-0.01)
StemCells, Inc. to Host Inaugural Investor and Analyst Event in New York
GlobeNewswire - Thu Nov 20, 9:11AM CST
StemCells, Inc. (Nasdaq:STEM), who pioneered the discovery and development of HuCNS-SC cells, a proprietary population of highly purified, expandable human neural stem cells and is leading the development of cell based therapies for the treatment of disorders of the central nervous system, will host its first investor and analyst event today, November 20, 2014, in New York.
STEM: 1.09 (-0.01)
A Timely Interview With BioTime's CEO And His Chief Commercial Officer
JMY Investments - at Seeking Alpha - Mon Nov 17, 10:39AM CST
BTX: 4.07 (+0.05), STEM: 1.09 (-0.01)
InVivo Therapeutics
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:56PM CST
STEM: 1.09 (-0.01), AST: 3.85 (+0.13), CUR: 3.41 (+0.13)
StemCells Inc. Faces Tough Times Ahead
Tom Franey - Seeking Alpha - Mon Nov 10, 9:36AM CST
StemCells Inc. (NASDAQ: STEM ) is a small cap biotech company primarily involved in stem cell research. Its stock is currently trading at $1.16, which is 50% of its recent highs. Disappointing Results In June of this year, STEM issued a press...
STEM: 1.09 (-0.01)
StemCells, Inc.: More Downside Risk Ahead
Biotech Research Group - Seeking Alpha - Fri Nov 07, 8:51AM CST
As an investor in the field of regenerative medicine and science, it is important to keep a focused eye on both the clinical accomplishments as well as the financial strength of the companies in which I invest. StemCells, Inc. (NASDAQ: STEM ) has...
STEM: 1.09 (-0.01)
StemCells beats by $0.12, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 7:24AM CST
STEM: 1.09 (-0.01)
StemCells, Inc. Reports Third Quarter 2014 Financial and Operating Results
GlobeNewswire - Wed Nov 05, 7:07AM CST
StemCells, Inc. (Nasdaq:STEM), which pioneered the discovery and development of HuCNS-SC cells, a proprietary population of highly purified, expandable human neural stem cells and is leading the development of cell based therapies for the treatment of disorders of the central nervous system, today reported financial results for the third quarter ended September 30, 2014.
STEM: 1.09 (-0.01)
